Zevra Therapeutics, Inc. (ZVRA)
Zevra Therapeutics: Worthy Of An Initial Holding
Zevra Therapeutics surged after Miplyffa's patent was listed in the FDA Orange Book, granting exclusivity through 2041. ZVRA achieved FY25 net sales of $87.4M, moved into profitability, retired all debt, and now holds $236.8M in cash and investments. The pipeline is focused on late-stage celiprolol for VEDS, with no clinical competition and FDA Orphan and Breakthrough Therapy designations.
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics: Miplyffa Uptake Validates Rare Disease Commercial Model
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability.
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, up 605% YoY, driven by MIPLYFFA, and is nearing profitability. ZVRA's valuation appears deeply discounted, with significant upside from EU expansion, pipeline assets Celiprolol and KP-1077, and a strong $200M cash position. FY26 is projected as the first year of true profitability, with analyst EPS estimates between $0.29 and $1.07 and revenue growth driven by MIPLYFFA.
Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript
Zevra Therapeutics, Inc. ( ZVRA ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nichol Ochsner - Vice President of Investor Relations & Corporate Communications Neil McFarlane - President, CEO & Director Joshua Schafer - Chief Commercial Officer R. Clifton - CFO & Treasurer Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Samantha Corwin - William Blair & Company L.L.C.
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.69 per share a year ago.
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)
Zevra Therapeutics (ZVRA) came out with a quarterly earnings of $1.21 per share versus the Zacks Consensus Estimate of $2.19. This compares to a loss of $0.48 per share a year ago.
Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript
Zevra Therapeutics, Inc. (NASDAQ:ZVRA ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adrian Quartel - Chief Medical Officer Joshua M. Schafer - Chief Commercial Officer Neil F.
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Zevra Therapeutics (ZVRA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of $1.43. This compares to a loss of $0.48 per share a year ago.
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'
Zevra Therapeutics (ZVRA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth
Zevra Therapeutics (ZVRA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to an 117.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
